Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

42,701 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A phase I trial of ganetespib in combination with paclitaxel and trastuzumab in patients with human epidermal growth factor receptor-2 (HER2)-positive metastatic breast cancer.
Jhaveri K, Wang R, Teplinsky E, Chandarlapaty S, Solit D, Cadoo K, Speyer J, D'Andrea G, Adams S, Patil S, Haque S, O'Neill T, Friedman K, Esteva FJ, Hudis C, Modi S. Jhaveri K, et al. Among authors: wang r. Breast Cancer Res. 2017 Aug 2;19(1):89. doi: 10.1186/s13058-017-0879-5. Breast Cancer Res. 2017. PMID: 28764748 Free PMC article. Clinical Trial.
Phase II Study of Weekly Paclitaxel with Trastuzumab and Pertuzumab in Patients with Human Epidermal Growth Receptor 2 Overexpressing Metastatic Breast Cancer: 5-Year Follow-up.
Wang R, Smyth LM, Iyengar N, Chandarlapaty S, Modi S, Jochelson M, Patil S, Norton L, Hudis CA, Dang CT. Wang R, et al. Oncologist. 2019 Aug;24(8):e646-e652. doi: 10.1634/theoncologist.2018-0512. Epub 2019 Jan 2. Oncologist. 2019. PMID: 30602614 Free PMC article. Clinical Trial.
Measuring Tumor Epichaperome Expression Using [124I] PU-H71 Positron Emission Tomography as a Biomarker of Response for PU-H71 Plus Nab-Paclitaxel in HER2-Negative Metastatic Breast Cancer.
Jhaveri KL, Dos Anjos CH, Taldone T, Wang R, Comen E, Fornier M, Bromberg JF, Ma W, Patil S, Rodina A, Pillarsetty N, Duggan S, Khoshi S, Kadija N, Chiosis G, Dunphy MP, Modi S. Jhaveri KL, et al. Among authors: wang r. JCO Precis Oncol. 2020 Nov 17;4:PO.20.00273. doi: 10.1200/PO.20.00273. eCollection 2020. JCO Precis Oncol. 2020. PMID: 33283132 Free PMC article.
A Phase I Study of Alpelisib in Combination with Trastuzumab and LJM716 in Patients with PIK3CA-Mutated HER2-Positive Metastatic Breast Cancer.
Jhaveri K, Drago JZ, Shah PD, Wang R, Pareja F, Ratzon F, Iasonos A, Patil S, Rosen N, Fornier MN, Sklarin NT, Chandarlapaty S, Modi S. Jhaveri K, et al. Among authors: wang r. Clin Cancer Res. 2021 Jul 15;27(14):3867-3875. doi: 10.1158/1078-0432.CCR-21-0047. Epub 2021 May 4. Clin Cancer Res. 2021. PMID: 33947692 Free PMC article. Clinical Trial.
Prognostic and predictive value of common mutations for treatment response and survival in patients with metastatic colorectal cancer.
Souglakos J, Philips J, Wang R, Marwah S, Silver M, Tzardi M, Silver J, Ogino S, Hooshmand S, Kwak E, Freed E, Meyerhardt JA, Saridaki Z, Georgoulias V, Finkelstein D, Fuchs CS, Kulke MH, Shivdasani RA. Souglakos J, et al. Among authors: wang r. Br J Cancer. 2009 Aug 4;101(3):465-72. doi: 10.1038/sj.bjc.6605164. Epub 2009 Jul 14. Br J Cancer. 2009. PMID: 19603024 Free PMC article.
An Integrative Approach to Inform Optimal Administration of OX40 Agonist Antibodies in Patients with Advanced Solid Tumors.
Wang R, Gao C, Raymond M, Dito G, Kabbabe D, Shao X, Hilt E, Sun Y, Pak I, Gutierrez M, Melero I, Spreafico A, Carvajal RD, Ong M, Olszanski AJ, Milburn C, Thudium K, Yang Z, Feng Y, Fracasso PM, Korman AJ, Aanur P, Huang SA, Quigley M. Wang R, et al. Clin Cancer Res. 2019 Nov 15;25(22):6709-6720. doi: 10.1158/1078-0432.CCR-19-0526. Epub 2019 Oct 1. Clin Cancer Res. 2019. PMID: 31573956 Clinical Trial.
42,701 results
You have reached the last available page of results. Please see the User Guide for more information.